Loading...
 
Mediterr J Rheumatol 2021;32(2):96-103
Biologic Therapies and Autoimmune Phenomena
Authors Information

Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece

Drosos AA , Pelechas E , Kaltsonoudis E , Markatseli TE , Voulgari PV 

References
  1. Drayton DL, Liao S, Mounzer RH, Ruddle NH. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol 2006;7(4):344-53.
  2. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345(5):340-50.
  3. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88.
  4. Burmester GR, Feist E, Dorner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014;10(2):77-88.
  5. Pichler WJ. Adverse side-effects to biological agents. Allergy 2006;61(8):912-20.
  6. Boyman O, Comte D, Spertini F. Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 2014;10(10):612-27.
  7. Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 2016;137(1):19-27.
  8. Ramos-Casals, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22(5):847-61.
  9. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011;31(11):1409-17.
  10. Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, et al. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 2017;35(4):579-85.
  11. Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2014;43(4):447-57.
  12. Voulgari PV, Drosos AA. Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 2006;6(12)1349-60.
  13. Papagoras Ch, Voulgari PV, Drosos AA. Golimumab, the newest TNF-α blocker, comes of age. Clin Exp Rheumatol 2015;33(4):570-7.
  14. Markatseli TE, Papagoras C, Nikoli A, Voulgari PV, Drosos AA. Certolizumab for rheumatoid arthritis. Clin Exp Rheumatol 2014;32(3):415-23.
  15. Pelechas E, Voulgari PV, Drosos AA. ABP 501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2018;18(3):317-22.
  16. Pelechas E, Drosos AA. Etanercept biosimilar SB-4. Expert Opin Biol Ther 2019;19(3):173-9.
  17. Markatseli TE, Theodoridou A, Zakalka M, Koukli E, Trantafyllidou E, Tsalavos S, et al. Persistence and adherence during the first six months of tocilizumab treatment among rheumatoid arthritis patients in routine clinical practice in Greece. Results from the single arm REMISSION II Study (NCT01649817). Mediterr J Rheumatol 2019;30(3):177-85.
  18. Pelechas E, Voulgari PV, Drosos AA. Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2019;15:1073-79.
  19. De Rycke L, Kruithof E, Van Damme N, Hoffman IEA, van den Bossche N, Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48(4).
  20. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43(11):2383-90.
  21. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann Rheum Dis 2005;64:403-7.
  22. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7(3):R545-R551.
  23. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008;37(6):381-7.
  24. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009;48(7):716-20.
  25. Ramos-Casals M, Perez-Alvarez R, Diaz Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9(3):188-93.
  26. Shovman O, Tamar S, Amital H, Watad A, Shoenfeld Y. Diverse patterns of anti-TNF-α induced lupus: case series and review of the literature. Clin Rheumatol 2018;37:563-8.
  27. Vaz JLP, Andrade CAF, Pereira AC, Martins Md FM, Levy RA. Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. Rev Bras Reumatol 2013;53(4):358-64.
  28. D’Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi AA, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-α antibodies. J Intern Med 2004;255(3):409-18.
  29. Wahren-Herlenius M, Dorner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013;382(9894):819-31.
  30. Chang C, Gershwin ME. Drugs and autoimmunity – a contemporary review and mechanistic approach. J Autoimmun 2010;34(3):J266-75.
  31. Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011;34(5):357-74.
  32. Reilly E, Edwards, C, Mackay K. Anti-TNF therapy induced arthritis in patients with inflammatory bowel disease. Rheumatology (Oxford) 2015;54(suppl 1):i94.
  33. Cobo-Ibáñez, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008;47(5):731-2.
  34. Korzenik J, Larsen MD, Nielsen F, Kjeldsen J, Nørgård BM. Increased risk of developing Crohn’s disease or ulcerative colitis in 17018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019;50(3):2890294.
  35. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents. Autoimmun Rev 2014;13(1):15-9.
  36. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005;52(8):2513-8.
  37. De Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143(2):223-31.
  38. Exarchou SA, Voulgari PV, Markatseli TE, Zioga A, Drosos AA. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009;38(5):328-31.
  39. Fréling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Bardaud A, et al. Cumulative incidence of, risk factor for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroneterol 2015;11(8):1186-96.
  40. Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA. Cutaneous autoimmune phenomena of the anti-TNFα biosimilars. Casebased Review. Curr Rheumatol Rev 2021;17(2):267-70.
  41. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202(1):135-43.
  42. Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005;102(9):3372-7.
  43. Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taïeb A. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009;161(5):1081-8.
  44. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007;56(8):2715-8.
  45. Mielke F, Schneider-Obermeyer J, Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008;67(7):1056-7.
  46. Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 2009;27(6):996-8.
  47. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004;16(3):180-5.
  48. Devos SA, van Den Bossche N, de Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003;206(4):388-90.
  49. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67(4):567-70. Doi: 10.1136/ard.2007.075663.
  50. Bonomo L, Ghoneim S, Levitt J. A case of granuloma annulare associated with secukinumab use. Case Rep Dermatol Med 2017:5918708.
  51. Clark ML, Tobin CA, Sutton A, Missall TA. Granuloma annulare in the setting of secukinumab. Case Rep Dermatol Med 2018:5175319.
  52. Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA. Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review. Rheumatol Int 2019;39(2):353-7.
  53. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol 2012;39(5):481-92.
  54. Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25(1):56-64.
  55. Bosch X, Saiz A, Ramos-Casals M. Monoclonal antibody therapy-associated neurologic disorders. Nat Rev Neurol 2011;7:165-72.
  56. Fernandez-Espartero MC, Perez-Zafrilla B, Nananjo A, Esteban C, Ortiz AM, Gomez-Reino JJ, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011;40(4):330-7.
  57. Andreadou E, Kemanetzoglou E, Brokalaki Ch, Evangelopoulos ME, Kilidireas C, Rombos A, et al. Demyelinating disease following anti-TNFα treatment: a causal or coincidental association? Report of four cases and review of the literature. Case Rep Neurol Med 2013;2013:671935.
  58. Faillace C, de Almeida JRM, de Carvalho JF. Optic neuritis after infliximab therapy. Rheumatol Int 2013;33:1101-3.
  59. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012;64(9):3043-51.
  60. Lin EJ, Reddy S, Shah VV, Wu JJ. A review of neurologic complications of biologic therapy in plaque psoriasis. Cutis 2018;101(1):57-60.
  61. Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol 2018:24(3):323-31.
  62. Islam MM, Poly TN, Yang HC, Wu CC, Li YC. Increase risk of multiple sclerosis in patients with psoriasis disease: an Evidence of observational studies. Neuroepidemiology 2019;52(3-4):152-60.
  63. Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurological adverse events in patients receiving anti-TNF therapy: aprospective imaging and electrophysiological study. Arthritis Res Ther 2014;16(3):R125.
  64. Kopp TI, Delcoigne B, Arkema EV, Jacobsen RK, Magyari M, Ibfelt EH, et al. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. Ann Rheum Dis 2020;79(5):566-72.
  65. Fee DB, Kasarskis EJ. Myasthenia gravis associated with etanercept therapy. Muscle Nerve 2009;39(6):866-70.
  66. Pelechas E, Memi T, Markatseli TE, Voulgari PV, Drosos AA. Adalimumab-induced myasthenia gravis: case-based review. Rheumatol Int 2020;40(11):1891-4.
  67. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Neuroinflammatory events after anti-TNFα therapy. Ann Rheum Dis May 2020;annrheumdis-2020-217723.
  68. Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev 2014;13(1):54-8.
  69. Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect 2011;17(12):1776-80.
  70. Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Pan GD. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011;65(3):546-51.
  71. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 2009;145(8):937-42.
  72. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011;41(2):256-64.
  73. Scrivo R, Spadaro A, Spinelli FR, Valesini G. Uveitis following the us of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum 2008;58(5):1555-6.
  74. Song IH, Appel H, Haibel H, Loddenkemper C, Braun J, Sieper J, et al. New onset of Crohn’s disease during treatment of active ankylosing spondylitis with etanercept. J Rheumatol 2008;35(3):532-6.
  75. Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009;48(8):883-6.